Pradeep has over 10 years of experience working in drug development and during this time played a significant leadership role in the pre-clinical, early-clinical development and experimental medicine strategy and execution of translational and clinical studies for a number of CNS targets. These include M1 agonist, H3 antagonist, D3 antagonist, 5-HT6 antagonist, Mu-opioid receptor antagonist, COMT inhibitor, Orexin 1 antagonist and D1 PAM for a number of indications including Alzheimer's disease, schizophrenia, Parkinson's disease, obesity and addiction. He is currently leading the experimental medicine and early-clinical development of compounds targeting muscarinic M1 and M4, mGlu5, and Orexin 1 receptors for various CNS indications.
Pradeep has also contributed to medical sciences and drug discovery/development through his significant contributions to scientific peer review and working across industry/academia boundaries to facilitate translational neuroscience and drug discovery/development efforts. He has been a member of the MRC's Developmental pathway funding scheme, Therapeutic target validation mental health and Industry asset sharing panels over the last five years and acted as a key opinion leader and advisor for the MRC's five-year mental health strategy. He has also been part of a Europeean-wide working group that brought together stakeholders from academia, industry and regulatory agencies to address many challenges in psychiatric drug development and stimulate research and development activity within industry.